[Skip to Navigation]
Comment & Response
October 2018

Pharmacogenetics in Psychiatry: A Companion, Rather Than Competitor, to Protocol-Based Care

Author Affiliations
  • 1Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada
  • 2Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
  • 3Department of Physiology & Pharmacology, University of Calgary, Calgary, Alberta, Canada
  • 4Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Toronto, Ontario, Canada
  • 5Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
JAMA Psychiatry. 2018;75(10):1090. doi:10.1001/jamapsychiatry.2018.2344

To the Editor The recent Viewpoint by Zubenko et al1 on pharmacogenetic tests for psychiatric treatment boldly states “the available evidence suggests Pgen [pharmacogenetic] tests will not contribute much to care.” However, we believe that the foundation from which the authors based their statement is incomplete and potentially misleading. Their statement has inadvertently assumed that (1) all pharmacogenetic testing is created equal with respect to their underlying scientific evidence and recommendations and (2) pharmacogenetic testing is incompatible with protocol-based care.

Add or change institution